Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4604330 | 0.98 | ALDH1A1 (0.66) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL853260 | 0.95 | ALDH1A1 (0.66) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL3441076 | 0.95 | ALDH1A1 (0.66) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL31710840 | 0.84 | ALDH1A1 (0.82) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL9741723 | 0.84 | ALDH1A1 (0.82) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL10492337 | 0.84 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL5828001 | 0.84 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL29783279 | 0.84 | POLB (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL5828004 | 0.84 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL133528 | 0.84 | POLB (0.68) | ALDH1A1POLBKDM4ETP53GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0345308-B1 | ORNITHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF METHOTREXATE RESISTANT CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-03-17 | — | — | EP | claimed |
| EP-1660093-B1 | AMMONIUM SALTS OF ORNITHINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | HANA BIOSCIENCES INC (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070219204-A1 | Pharmaceutically active ornitihine derivatives, ammonium salts thereof and methods of making same | DANA-FARBER CANCER INSTITUTE | 2007-09-20 | — | — | US | disclosed |
| CN-1780631-A | anticancer phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| US-20060079531-A1 | Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same | DANA-FARBER CANCER INSTITUTE | 2006-04-13 | — | — | US | disclosed |
| EP-1638973-A1 | PHARMACEUTICALLY ACTIVE ORNITHINE DERIVATIVES, AMMONIUM SALTS THEREOF AND METHODS OF MAKING SAME | DANA-FARBER CANCER INSTITUTE (US) | 2006-03-29 | — | — | EP | disclosed |
| US-6989386-B2 | Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same | DANA-FARBER CANCER INSTITUTE (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050032807-A1 | Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives | HANA BIOSCIENCES, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2004094427-A1 | PHARMACEUTICALLY ACTIVE ORNITHINE DERIVATIVES, AMMONIUM SALTS THEREOF AND METHODS OF MAKING SAME | DANA-FARBER CANCER INSTITUTE (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040072837-A1 | Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-04-15 | — | — | US | disclosed |
| EP-0345308-B1 | ORNITHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF METHOTREXATE RESISTANT CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0345308-A4 | ORNITHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF METHOTREXATE RESISTANT CELLS. | DANA FARBER CANCER INST INC (US) | 1990-05-14 | — | — | EP | disclosed |
| EP-0345308-A1 | ORNITHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF METHOTREXATE RESISTANT CELLS. | DANA FARBER CANCER INST INC (US) | 1989-12-13 | — | — | EP | disclosed |
| WO-1989004312-A1 | ORNITHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF METHOTREXATE RESISTANT CELLS | DANA-FARBER CANCER INSTITUTE (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072837-A1 | Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same | OTC, OAT, DOHH | ALDH1A1 1130/4885POLB 2230/4885KDM4E 879/4885 |
| US-20050032807-A1 | Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives | ARG1, OTC, OAT | ALDH1A1 1371/4885POLB 2194/4885KDM4E 1181/4885 |
| US-20060079531-A1 | Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same | OTC, OAT, ODC1 | ALDH1A1 1286/4885POLB 1531/4885KDM4E 719/4885 |
| US-20070219204-A1 | Pharmaceutically active ornitihine derivatives, ammonium salts thereof and methods of making same | OTC, OAT, ODC1 | ALDH1A1 1751/4885POLB 2100/4885KDM4E 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.